TY - JOUR
T1 - Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant <em>Mycobacterium tuberculosis</em>
JF - Antimicrobial Agents and Chemotherapy
JO - Antimicrob. Agents Chemother.
DO - 10.1128/AAC.01489-18
VL - 63
IS - 2
SP - e01489-18
AU - van Rijn, Sander P.
AU - Zuur, Marlanka A.
AU - Anthony, Richard
AU - Wilffert, Bob
AU - van Altena, Richard
AU - Akkerman, Onno W.
AU - de Lange, Wiel C. M.
AU - van der Werf, Tjip S.
AU - Kosterink, Jos G. W.
AU - Alffenaar, Jan-Willem C.
Y1 - 2019/02/01
UR - http://aac.asm.org/content/63/2/e01489-18.abstract
N2 - Multi- and extensively drug-resistant tuberculosis (M/XDR-TB) has become an increasing threat not only in countries where the TB burden is high but also in affluent regions, due to increased international travel and globalization. Carbapenems are earmarked as potentially active drugs for the treatment of Mycobacterium tuberculosis. To better understand the potential of carbapenems for the treatment of M/XDR-TB, the aim of this review was to evaluate the literature on currently available in vitro, in vivo, and clinical data on carbapenems in the treatment of M. tuberculosis and to detect knowledge gaps, in order to target future research. In February 2018, a systematic literature search of PubMed and Web of Science was performed. Overall, the results of the studies identified in this review, which used a variety of carbapenem susceptibility tests on clinical and laboratory strains of M. tuberculosis, are consistent. In vitro, the activity of carbapenems against M. tuberculosis is increased when used in combination with clavulanate, a BLaC inhibitor. However, clavulanate is not commercially available alone, and therefore, it is impossible in practice to prescribe carbapenems in combination with clavulanate at this time. Few in vivo studies have been performed, including one prospective, two observational, and seven retrospective clinical studies to assess the effectiveness, safety, and tolerability of three different carbapenems (imipenem, meropenem, and ertapenem). We found no clear evidence at the present time to select one particular carbapenem among the different candidate compounds to design an effective M/XDR-TB regimen. Therefore, more clinical evidence and dose optimization substantiated by hollow-fiber infection studies are needed to support repurposing carbapenems for the treatment of M/XDR-TB.
ER -